AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33856973
Drug: Forgiveness therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forgiveness therapy
Trial: 35488019
Drug: High subcutaneous
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High subcutaneous adipose tissue radiation attenuation (SAT-RA Z-score)
Trial: 35220182
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg every three weeks for one year)
Trial: 35220182
Drug: β-blockers (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockers (oral administration within 30 days of randomisation)
Trial: 35220182
Drug: Pembrolizumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab with β-blockers
Trial: 35220182
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with β-blockers
Trial: 35220182
Drug: Pembrolizumab without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab without β-blockers
Trial: 32985064
Drug: High-dose THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose THC (20 or 25 mg)
Trial: 33220252
Drug: Anti-H pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-H pylori therapy
Trial: 36423863
Drug: Online self-administered
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online self-administered cognitive behavioral therapy with guided peer support
Trial: 36423863
Drug: Therapist-administered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-administered cognitive behavior therapy
Trial: 33470139
Drug: Cenobamate (CNB)
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cenobamate (CNB) as adjunct therapy
Trial: 33812743
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of 13-valent pneumococcal conjugate vaccine (PCV13)
Trial: 34815165
Drug: SMS reminders
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS reminders for medication intake (first to seventh postoperative days)
Trial: 34468869
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W for up to 35 cycles
Trial: 33864481
Drug: Neck‐worn position
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck‐worn position therapy device (PTD)
Trial: 32549196
Drug: Oral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral appliance (OA)
Trial: 35001638
Drug: Tadalafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (20 mg daily)
Trial: 32560746
Drug: Dornase alfa
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dornase alfa (Pulmozyme®, Roche, Switzerland) administered by aerosol, at a dose of 2500 IU twice daily for 7 consecutive days.
Trial: 35351187
Drug: Accelerometer measured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerometer measured average daily minutes of brisk walking (≥ 100 steps/min)
Trial: 36433662
Drug: Bioactive collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioactive collagen peptides (CP) 15 g daily
Trial: 34535037
Drug: Apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 2.5 mg bid
Trial: 32386271
Drug: Bipolar sealing
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar sealing device (BSD) with suture augmentation (4-0 polydioxanone)
Trial: 32386271
Drug: Bipolar sealing
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar sealing device (BSD) without suture augmentation
Trial: 33325259
Drug: HI-FIVES intervention
RxNorm normalized name: Eucalyptus dives leafy twig oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HI-FIVES intervention (three weekly facilitated training calls covering five education topics)
Trial: 33836878
Drug: Tocilizumab at
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab at 8 mg/kg on day -1 and abatacept at 10 mg/kg on days 0, 7, 14, and 28
Trial: 33836878
Drug: Historical cohort
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical cohort received rabbit ATG at 5 mg/kg total dose
Trial: 33810804
Drug: Transcutaneous tibial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous tibial nerve stimulation (TTNS) therapy
Trial: 32412598
Drug: Theracurmin® (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theracurmin® (360 mg/day)
Trial: 34096894
Drug: Exemestane treatment
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane treatment
Trial: 33462653
Drug: Annual zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Annual zoledronic acid (ZOL) infusion (5 mg) at 1 week, 12 months, and 24 months after surgery
Trial: 89120227
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone treatment
Trial: 32272518
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CaHA and MFU-V
Trial: 32660282
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 mg every-8-weeks
Trial: 33123819
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of caffeine
Trial: 35831082
Drug: Short list
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short list of essential medicines
Trial: 33836963
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia (L group)
Trial: 34153231
Drug: High-dose induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose induction adalimumab (2·4 mg/kg at weeks 0 and 1)
Trial: 34153231
Drug: Standard-dose induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose induction adalimumab (2·4 mg/kg at week 0 and placebo at week 1)
Trial: 34153231
Drug: Standard-dose maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose maintenance adalimumab (0·6 mg/kg every other week)
Trial: 34153231
Drug: Pooled adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pooled adalimumab groups (high-dose and standard-dose)
Trial: 35057489
Drug: 5.5 g
RxNorm normalized name: honey 5.5 gram/5 mL ORAL SYRUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.5 g of BiotisTM GOS
Trial: 34117528
Drug: 3× weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3× weekly bicycle ergometer training during HD for 12 weeks
Trial: 32371534
Drug: Standard-of-care medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care medical treatment (MED)
Trial: 35275009
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride solution (ISCL)
Trial: 34582448
Drug: Sunflower seed
RxNorm normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower seed oil (SSO) emollient therapy; 10 ml applied 3 times daily throughout the neonatal period.
Trial: 34814835
Drug: Expert-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expert-based medication review
Trial: 33941123
Drug: Work-related medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work-related medical rehabilitation program (at least 11 hours of work-related treatment modules)
Trial: 33151615
Drug: 0.05% tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tomato lycopene and 3.45% wheat bran extract cream applied twice a day for three months with SPF 30 sunscreen
Trial: 33151615
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied twice a day for three months with SPF 30 sunscreen
Trial: 35428645
Drug: Digital behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital behavioural health treatment for chronic pain
Trial: 33809130
Drug: Flaxseed (FS)
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (FS) dietary intervention, 10 g/d for 6 weeks
Trial: 32088670
Drug: Eucalyptus solution
DrugBank: Eucalyptus gum (DB15537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eucalyptus solution 5% inhalation 3 times/day for 20 minutes (every 8 hours)
Trial: 36482231
Drug: 2 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg/kg alfentanil
Trial: 36482231
Drug: 4 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 μg/kg alfentanil
Trial: 36482231
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of alfentanil (2, 3, 4 μg/kg)
Trial: 35688164
Drug: tixagevimab-cilgavimab 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tixagevimab-cilgavimab 600 mg (two consecutive 3 mL intramuscular injections, 300 mg tixagevimab and 300 mg cilgavimab)
Trial: 35688164
Drug: tixagevimab-cilgavimab 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tixagevimab-cilgavimab 600 mg
Trial: 32334703
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg or 600 mg loading dose, then 75 mg once daily for 12 months)
Trial: 32334703
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg loading dose, then 90 mg twice daily for 12 months)
Trial: 36254029
Drug: Religious Rational
RxNorm normalized name: red delicious apple allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Religious Rational Emotive Behavior Therapy (RREBT) for 12 weeks
Trial: 33034015
Drug: Intra-gastric balloon
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-gastric balloon (IGB) therapy
Trial: 34676663
Drug: Ibrexafungerp (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrexafungerp (300 mg twice for 1 day)
Trial: 35783610
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma therapy
Trial: 35783610
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no convalescent plasma therapy)
Trial: 33901921
Drug: Granulocyte-colony stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony stimulating factors (G-CSF)
Trial: 35059803
Drug: 70 kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 kVp tube voltage, Smart mA for noise index (NI) of 36HU, contrast dose rate of 16mgI/kg/s, and DLIR-H
Trial: 35059803
Drug: 120 kVp,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 kVp, Smart mA for NI of 25HU, contrast dose rate of 32mgI/kg/s, and 60% ASIR-V
Trial: 35987298
Drug: Generic cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic cognitive‐behavioral therapy (CBT) treatment
Trial: 35987298
Drug: Modified (social
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified (social anxiety) treatment
Trial: 33151330
Drug: No insomnia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No insomnia treatment
Trial: 32598468
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch plus nicotine gum (8 weeks)
Trial: 32598468
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch plus nicotine gum (26 weeks)
Trial: 32738019
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (intervention group) for 6 months
Trial: 34587567
Drug: Intermittent theta
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent theta burst stimulation (iTBS) to the cerebellar midline, administered 5 times/week for 2 weeks.
Trial: 32405757
Drug: Nicotine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (7 mg/24 h transdermally)
Trial: 34192885
Drug: Tolperisone administered
RxNorm normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolperisone administered orally three-times daily for 14 days
Trial: 33518129
Drug: In ovo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In ovo injection of organic microminerals (zinc, manganese, and copper)
Trial: 34987600
Drug: Mild hypothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hypothermia therapy
Trial: 33459079
Drug: Self-managed computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-managed computer therapy
Trial: 34378260
Drug: 4% Pistacia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% Pistacia atlantica ointment, applied topically three times a day for 8 weeks
Trial: 34378260
Drug: Placebo ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment, applied topically three times a day for 8 weeks
Trial: 32709430
Drug: Pranayama breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranayama breathing exercise group (PBE-G; n = 15)
Trial: 32709430
Drug: Conventional breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional breathing exercise group (CBE-G; n = 15)
Trial: 32444038
Drug: Benson's Relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benson's Relaxation Response (BRR) administered twice a day over 5 consecutive days
Trial: 35606022
Drug: Regular, low-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular, low-dose, sustained-release morphine
Trial: 36164102
Drug: Tafasitamab (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafasitamab (12 mg/kg IV on days 1, 8, 15, and 22 of a 28-day cycle for cycles 1-3, then days 1 and 15 for cycles 4-12) plus Lenalidomide (20 mg PO QD, days 1-21/cycle for 12 cycles) and Rituximab (375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1, then day 1 of cycles 2-5)
Trial: 36164102
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline solution IV) plus Lenalidomide and Rituximab
Trial: 33393645
Drug: BNP (B-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP (B-type natriuretic peptide) via intravenous infusion, 2 µg/kg bolus followed by infusion at 0.01, 0.02, and 0.03 µg/kg/min for 1.5 hours
Trial: 36113061
Drug: Ultrasound-guided peripheral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided peripheral intravenous catheters (PIVC)
Trial: 38912927
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) therapy
Trial: 33049392
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (27.5 μg) 2 sprays once daily for 1 week, followed by as-needed use for 5 weeks (FF-as-needed)
Trial: 33189909
Drug: Topical gelatin-thrombin
RxNorm normalized name: thrombin Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gelatin-thrombin matrix sealant (TGTMS)
Trial: 34151818
Drug: Progressive Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive Muscle Relaxation Therapy (PMRT)
Trial: 34551211
Drug: 3D-CRT (Three-Dimensional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D-CRT (Three-Dimensional Conformal Radiation Therapy)
Trial: 34310904
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor inhibitors (apalutamide, enzalutamide, or daralutamide)
Trial: 32503517
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose yoga (LD), 60 min per week
Trial: 32503517
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose yoga (MD), 150 min per week
Trial: 33044394
Drug: EMONO (1-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMONO (1-hour administration of equimolar mixture of oxygen and nitrous oxide)
Trial: 35590386
Drug: Intravenous tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tenecteplase 0.25 mg/kg
Trial: 32199541
Drug: Work Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work Therapy (WT)
Trial: 36156571
Drug: Modified Constraint-Induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Constraint-Induced Movement Therapy (MCIMT)
Trial: 32088365
Drug: Positive Psychology
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive Psychology (PP) intervention, 8-session weekly phone-delivered group format
Trial: 91213894
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g wheat bran (WB)
Trial: 91213894
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g sugar-beet fiber (SBF)
Trial: 34184295
Drug: Melatonin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (10 mg orally for 24 weeks)
Trial: 34184295
Drug: Melatonin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (10 mg orally for 24 weeks) in nondiabetic patients
Trial: 32576151
Drug: Lidocaine by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine by continuous intravenous administration
Trial: 32151247
Drug: Sulfonylurea therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea therapy
Trial: 32760144
Drug: Aussie-FIT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aussie-FIT intervention (12 weekly 90-min sessions)
Trial: 33354803
Drug: Placebo treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatments
Trial: 35436823
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of low-dose hydrocortisone therapy
Trial: 32166624
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment with pantoprazole (40 mg once daily)
Trial: 33578661
Drug: Preventive outreach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive outreach educational intervention (oral health education in two one-hour sessions)
Trial: 35247906
Drug: Famitinib, Camrelizumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famitinib, Camrelizumab, and Nab-paclitaxel combination
Trial: 36213563
Drug: Oral implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral implant restoration
Trial: 36091017
Drug: Renin-angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system inhibitors (RASi) at maximum tolerant dose for 3 months
Trial: 34168292
Drug: Contemporary matched
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contemporary matched conventional therapy group (CTG)
Trial: 33070144
Drug: Topical cidofovir
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical cidofovir (first-line therapy)
Trial: 33070144
Drug: Topical foscavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical foscavir (first-line therapy)
Trial: 33070144
Drug: Intravenous foscavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous foscavir (first-line therapy)
Trial: 33070144
Drug: Intravenous foscavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous foscavir (second-line therapy)
Trial: 34704711
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL normal saline
Trial: 34541941
Drug: Glucose-containing dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-containing dialysate (5.55 mmol/L)
Trial: 35104042
Drug: Topical turmeric
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical turmeric cream
Trial: 33342523
Drug: Treatment schools
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment schools with access to free breakfast, lunch, and supper on school days, and a food backpack on weekends and school breaks
Trial: 35879482
Drug: Isocaloric/isonitrogenous control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric/isonitrogenous control supplement
Trial: 35656683
Drug: Honey solution
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey solution (5 mL)